Fujian medical university union hospital
Fuzhou, Fujian, 350000, China
NCT Number: NCT06938139
The Benchmark-MISGC study was a large-scale retrospective observational study launched by the China Gastric Cancer Surgical Union, aiming to establish the benchmarks of the short- and long-term outcomes for gastric cancer patients who underwent minimal invasive gastrectomy.
This study is active but is not currently recruiting participants.
Notify MeAll sexes
Observational
Fuzhou, Fujian, 350000, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
None, observational study
Time frame: 30 days
Median values of continuous variables and the proportions of categorical variables were calculated per participating centre. Benchmark values, indicating 'best achievable' results for each outcome indicator, were set at the 25th percentile for positive parameters (for example lymph node yield) or the 75th percentile for negative parameters (for example complications) of the centers' median values. Postoperative complications were evaluated within 30 days following surgery. These postoperative complications include gastrointestinal-related complications, incision-related complications, respiratory complications, cardiovascular and cerebrovascular complications, urinary system complications, infection complications, embolism complications, and other complications. The grading of postoperative complications adopts the Clavien-Dindo classification.
Time frame: 1-year, 2-year and 3-year
Benchmark values of 1-year, 2-year and 3-year OS. OS was defined as the time from surgery to death from any cause or last follow-up.
Time frame: 1-year, 2-year, and 3-year
Benchmark values of 1-year, 2-year and 3-year DSS. DSS was defined as the time from surgery to death from gastric cancer, or last follow-up.
Time frame: 1 month
the number of harvest lymph nodes
Time frame: 30 days
Patient died during hospitalization.
Time frame: 1 days
Intraoperative complications were defined as bleeding due to named vessel injury, injury to visceral organs, mechanical factor-related problems, cardiopulmonary dysfunction due to hypercapnia, and other complications
Time frame: 1 day
Intraoperative blood loss
Time frame: 1 day
From skin incision to skin closure
Time frame: 30 days
Textbook outcome (TO) was defined based on review of existing TO metrics in the literature including outcomes such as complete-potentially curative status, no intraoperative complications, no eventful postoperative complications (Clavien-Dindo grade III or higher), 15 lymph nodes(LNs) examined, hospital stay < 21days, no reintervention (surgical, endoscopic or radiological) within 30 days after surgery, no readmission to the intensive care unit (ICU) within 30 days after surgery, no postoperative mortality within 30 days after surgery, and no hospital readmission within 30 days after discharge. When all nine desired health outcomes were realized, TO was achieved.
Fujian Medical University
Other
Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy: A Multicentre Analysis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06914687
Digestive System Diseases, Digestive System Neoplasms
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT05476796
Adenocarcinoma, Adenocarcinoma Of Esophagus
Amiens, France
View Trial DetailsNCT07522320
Digestive System Diseases, Digestive System Neoplasms
Portalegre, Portugal
View Trial DetailsNCT04523818
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8
Houston, Texas, United States
View Trial Details